Max Healthcare

KKR Invests in Healthcare Revenue Solutions Provider Infinx

Retrieved on: 
星期二, 五月 21, 2024
Professional Services, Data Management, Technology, Other Technology, Finance, Software, Cloud, Partnership, Rothschild & Co, Patient, RCM, MYOB, Hospital, Automation, Organization, Health, Investment, Cloudera, Ness Digital Engineering, KKR, Growth, Acquisition, Jaideep, Norwest Venture Partners, Max Healthcare, Multimedia, JB

KKR, a leading global investment firm, and Infinx Services Private Limited (“Infinx” or the 'Company'), an AI-driven healthcare revenue cycle solutions provider, today announced the acquisition of a significant minority stake in Infinx by a KKR-managed fund.

Key Points: 
  • KKR, a leading global investment firm, and Infinx Services Private Limited (“Infinx” or the 'Company'), an AI-driven healthcare revenue cycle solutions provider, today announced the acquisition of a significant minority stake in Infinx by a KKR-managed fund.
  • View the full release here: https://www.businesswire.com/news/home/20240520027338/en/
    Co-founded in 2012 by Sandeep Tandon and Jaideep Tandon, Infinx is a provider of innovative, data-driven revenue cycle management solutions for the healthcare sector, with a particular focus on the US market.
  • Infinx’s Healthcare Revenue Cloud platform supports end-to-end revenue cycle business functions utilizing AI, automation, payer integration, and workforce management.
  • Infinx counts over 400 leading healthcare provider organizations as customers including hospitals, health systems and outpatient healthcare providers.

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors

Retrieved on: 
星期二, 二月 13, 2024
Therapy, School, Sir Ratan Tata Trust, Cadila Pharmaceuticals, Entrepreneurship, AI, Investment, Growth, Silicon, Senior advisor, AACR, Roche, Lead, Partner, Leber's hereditary optic neuropathy, Trustee, Patient, SIX Swiss Exchange, Knowledge, Max Healthcare, Stanford University, Pharmaceutical industry

“We are thrilled to announce the addition of Dr. Singh and Dr. Meier to the Board of Directors of Onconetix,” stated Chairman of the Board James Sapirstein.

Key Points: 
  • “We are thrilled to announce the addition of Dr. Singh and Dr. Meier to the Board of Directors of Onconetix,” stated Chairman of the Board James Sapirstein.
  • Dr. Singh serves as an Adjunct Professor in the School of Medicine at Stanford, where he teaches clinical diagnostics and entrepreneurship.
  • Dr. Singh has held several board positions including Lead Director at Max Healthcare, board member at Cadila Pharmaceuticals, and Senior Advisor to the Tata Trusts Cancer program.
  • He is co-founder, board member and advisor for several biotech companies in Switzerland and the US.

bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition

Retrieved on: 
星期四, 十一月 2, 2023
Health, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, Hemoglobinopathy, FDA, MSCE, PDUFA, Busulfan, Food, LVV, SCD, History, Sickle cell disease, Ronas Voe, Prescription Drug User Fee Act, Data, Children's Hospital of Philadelphia, Thalassemia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TDT, Max Healthcare, University of Pennsylvania, Pediatrics, Society, ASH, Priority review, Quality of life, San Diego Convention Center, Division, HRQOL, Perelman School of Medicine at the University of Pennsylvania, University, Exposition, Month, Hospital, BLA, Betibeglogene autotemcel, Pharmaceutical industry, Vaccine, Patient, Quality of life (healthcare), Safety, Hematology

The meeting will take place December 9-12, 2023 at the San Diego Convention Center and online.

Key Points: 
  • The meeting will take place December 9-12, 2023 at the San Diego Convention Center and online.
  • lovo-cel treatment regimen largely reflects known side effects of hematopoietic stem cell collection and busulfan conditioning regimen and underlying sickle cell disease.
  • Updated iron management outcomes demonstrating sustained improvements in iron burden, with the majority of patients able to stop iron chelation therapy, will also be presented.
  • Safety of beti-cel treatment largely reflects the known side effects of hematopoietic stem cell collection and busulfan conditioning regimen.

More Aggressive Treatment Doesn't Impact Quality of Life for Metastatic Colorectal Cancer Patients, According to New Study in JNCCN

Retrieved on: 
星期四, 十月 12, 2023
Neoplasm, Quality of life, CAPOX, Max Healthcare, Penn Medicine Princeton Medical Center, Bevacizumab, Risk, Radiation, EORTC, SAE, Șaeș, Survival, Outline of health sciences, University, Disease, FOLFOX, Patient, Quality of life (healthcare), FACP, University of Pennsylvania Health System, Fatigue, Medicine, Journal of the National Comprehensive Cancer Network, National Comprehensive Cancer Network, Overalls, Face, Perelman Center for Advanced Medicine, Research, Pharmaceutical industry, Nursing, Medical imaging, Life, MD

PLYMOUTH MEETING, Pa., Oct. 12, 2023 /PRNewswire/ -- New research in the October 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that intensive local-regional treatment to remove as much tumor as possible (known as "debulking"), in addition to standard systemic therapy, does not impact overall quality of life significantly for people with metastatic colorectal cancer.

Key Points: 
  • Significant adverse events were reported in 21% of patients in the standard group and 43% of patients who also received tumor debulking.
  • However, there were no statistical or clinically relevant differences according to patient-reported outcomes for overall health-related quality of life or fatigue.
  • "This could mean that the negative impact of complications on quality of life is temporary and eventually balances out with a decrease in tumor-related symptoms after treatment.
  • "Given the considerable amount of complications from local treatment, we had expected to see a bigger impact on overall and persistent quality of life in the experimental group.

Chronus Health Appoints Dr. Ajit Singh as Chairman of the Board of Directors

Retrieved on: 
星期四, 六月 8, 2023
Columbia University, Conditional sentence, Bachelor, Executive, AACR, Max Healthcare, The Washington Campus Board of Directors, Senior advisor, Roche, COVID-19, Cancer, Ageing, Stanford University, COVID-19 testing, Computer, Sir Ratan Tata Trust, Organization, Silicon, Syracuse University, Book, Entrepreneurship, Partner, Trustee, School, Master, Knowledge, Computer science, Banaras Hindu University, Electricity, Virginia Tech Carilion School of Medicine and Research Institute, Medical device, Management, Medicine

FREMONT, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Chronus Health, Inc. , a disruptor in point-of-care diagnostics, today announced it has appointed Dr. Ajit Singh as Chairman of the company's Board of Directors.

Key Points: 
  • FREMONT, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Chronus Health, Inc. , a disruptor in point-of-care diagnostics, today announced it has appointed Dr. Ajit Singh as Chairman of the company's Board of Directors.
  • Dr. Singh is currently a Partner at Artiman Ventures, a Silicon Valley-based venture capital firm, serving on the Board of Directors of several life sciences and healthcare portfolio companies.
  • He is also an Adjunct Professor in the School of Medicine at Stanford, where he teaches diagnostics and entrepreneurship.
  • In addition, he is a member of the Board of Trustees of the American Association for Cancer Research (AACR) Foundation.

Urologists Explore Environmental Exposures and Bladder Cancer

Retrieved on: 
星期五, 四月 28, 2023
Survivor, Abstract, Risk, Mechanics, University, Interview, Augusta University, Occupational exposure limit, Medical college, Communication, Max Healthcare, Quality of life, American Urological Association, Chapel Hill, Bladder cancer, University of North Carolina at Chapel Hill football scandal, National Cancer Institute, Solvent, Chapel, MD, Patient, Research, MPH, Smoking, UTHealth School of Dentistry, Urinary bladder, Dietary supplement, Doctor of Philosophy

Do automobile mechanics, shoemakers and painters have a higher risk of bladder cancer?

Key Points: 
  • Do automobile mechanics, shoemakers and painters have a higher risk of bladder cancer?
  • Researchers will be presenting these bladder cancer and environmental exposure study findings at the 118th Annual Scientific Meeting of the American Urological Association.
  • Stella Koutros, PhD, MPH, from the National Cancer Institute, evaluated exposure to solvents and risk of bladder cancer in 1182 incident cases and 1408 controls from a population-based study.
  • "There is a lot of unknown between certain environmental exposures and bladder cancer so new data needs to be disseminated."

Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Retrieved on: 
星期二, 三月 7, 2023
Health, Infectious Diseases, Stem Cells, Health Technology, Clinical Trials, Pharmaceutical, Biotechnology, History, Gastrointestinal tract, Priority review, Pharmacology, JAMA, JAMA Network Open, DSMB, Infection, David Berry (inventor), Cirrhosis, Journal, CDI, ACG, Therapy, UC, Incidence, The New England Journal of Medicine, Graft-versus-host disease, Max Healthcare, Research, Clostridioides difficile infection, Breakthrough therapy, Mayo Clinic, Hematopoietic stem cell transplantation, GI, American College of Gastroenterology, Data monitoring committee, Recurrence, Memorial Sloan Kettering Cancer Center, American Medical Association, Bloodstream infections, Patient, Cohort, University, Conference, FDA, NUALS Arts and Literary Annual Meet, Harvard Medical School, HRQOL, University of Chicago Medical Center, American College, Variometer, Safety, NEJM, PDUFA, Pharmaceutical industry, Vaccine, Cryptocurrency

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2022 financial results and provided business updates.

Key Points: 
  • Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today reported fourth quarter and full year 2022 financial results and provided business updates.
  • In February 2023, Seres announced the publication of Phase 3 ECOSPOR IV trial results in JAMA Network Open and results were also shared at the IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meetings.
  • Research and development expenses for the fourth quarter of 2022 were $46.2 million, compared with $36.8 million for the same period in 2021.
  • General and administrative expenses for the fourth quarter of 2022 were $22.4 million, compared with $20.5 million for the same period in 2021.

Global Home Healthcare Services Market 2022-2026 - ResearchAndMarkets.com

Retrieved on: 
星期四, 四月 28, 2022
Health, General Health, Patient satisfaction, LHC, Max Healthcare, Sutter Health, Bluebird Care, CVS Health, Amedisys, Retail, Grand

This study identifies the increasing acceptance of connected healthcare among healthcare services as one of the prime reasons driving the home healthcare services market growth during the next few years.

Key Points: 
  • This study identifies the increasing acceptance of connected healthcare among healthcare services as one of the prime reasons driving the home healthcare services market growth during the next few years.
  • Also, technological advancements in global home healthcare services and increased incidences of life-threatening diseases will lead to sizable demand in the market.
  • The market is driven by rising geriatric population, large areas of application, and improvement in quality of global home healthcare services and increased patient satisfaction.
  • Also, the home healthcare services market analysis report includes information on upcoming trends and challenges that will influence market growth.

Global Outpatient Hospital Services (Treatment Services, Diagnostic Tests, Minor Surgical Procedures) Markets, Competition, Forecast & Opportunities, 2016-2021 & 2022-2026 - ResearchAndMarkets.com

Retrieved on: 
星期二, 三月 29, 2022
Health, Hospitals, Conditional sentence, Emergency department, Diagnosis, Percussion section, Growth, Netcare, Research, Max Healthcare, Non-functional testing, Community Health Systems, Tenet Healthcare, Apollo Hospitals, HCA Healthcare, Fortis Healthcare, Tertiary referral hospital, Patient, Hospital, Medical device

Global outpatient hospital services market will witness significant growth in the forecast period, 2022-2026.

Key Points: 
  • Global outpatient hospital services market will witness significant growth in the forecast period, 2022-2026.
  • Additionally high treatment cost for inpatient treatment is inclining the consumers to opt for outpatient hospital services and thus aiding to the growth of the global outpatient hospital services market in the next five years.
  • Outpatient hospital services are the healthcare services that are provided to the patients often suffering from chronic or lifestyle diseases.
  • The advanced technology has made it possible for the healthcare industry to provide excellent healthcare services through outpatient hospital services.

Telemetrix Finalizes Board With Four Key Members

Retrieved on: 
星期二, 八月 17, 2021
Data Management, Health, Technology, Hospitals, Practice Management, Software, General Health, BBA, ID, Care Quality Commission, Chamber of commerce, Blake School, Board, Max Healthcare, Miami University, State, CTO, VOIP, BA, University, Harvard University, Business, Computerworld, Board of directors, HCA Healthcare, CPA, Investment, HCA, Technology, Data science, Industry, Hay, Lee University, Commerce, Asia, MBA, Senior advisor, Goal, Organization, US, Lists of schools in England, EDRM, WebMD, Growth, PGi, CSO, NHS, CPO, Chairperson, Management

Telemetrix recently announced the addition of four new members to its Board of Directors who cross international industry and expertise lines to promote Telemetrix rapid growth.

Key Points: 
  • Telemetrix recently announced the addition of four new members to its Board of Directors who cross international industry and expertise lines to promote Telemetrix rapid growth.
  • New board members include:
    Michael Neeb is a 30-year healthcare veteran with extensive global healthcare system experience.
  • We are so please to add these prestigious members to the Telemetrix Board, offers C. Micah Spruill, CSO.
  • It also means that Telemetrix offers features, services, and health data analytics no other remote patient monitoring provider can offer.